Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia

$30M Series A extension and Phase 1b/2a trial initiation signal capital and clinical catalysts for LTX-001.